{"transactions":[{"id":1770579,"issuer":{"id":8499,"kind":"organization","name":"Transcode Therapeutics, Inc.","symbol":"RNAZ"},"owners":[{"id":109315,"kind":"person","name":"Dudley Robert Michael","position":1,"cik":"0001854161","reported_name":"Dudley Robert Michael","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-10-02T16:37:49.000Z","date":"2023-09-28","kind":"purchase","planned":false,"acquired":true,"shares":98000,"price":0.51,"value":49980.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares acquired pursuant to an underwritten public offering of common stock by the Issuer."}],"balance_after":180262,"source":{"system":"sec-edgar","filing":"0001104659-23-105924","document":"tm2327413-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1854161/000110465923105924/tm2327413-1_4seq1.xml","form_type":"4"}},{"id":1846657,"issuer":{"id":8499,"kind":"organization","name":"Transcode Therapeutics, Inc.","symbol":"RNAZ"},"owners":[{"id":109315,"kind":"person","name":"Dudley Robert Michael","position":1,"cik":"0001854161","reported_name":"Dudley Robert Michael","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-06-22T18:23:24.000Z","date":"2023-06-21","kind":"purchase","planned":false,"acquired":true,"shares":12000,"price":2.6515,"value":31818.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Reflects the weighted average purchase price for shares of common stock purchased. Actual purchase prices for the shares purchased ranged from $2.60 to $2.70. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission full information regarding the number of shares purchased at each separate price."}],"balance_after":82262,"source":{"system":"sec-edgar","filing":"0001104659-23-073872","document":"tm2319496-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1854161/000110465923073872/tm2319496-1_4seq1.xml","form_type":"4"}},{"id":1846656,"issuer":{"id":8499,"kind":"organization","name":"Transcode Therapeutics, Inc.","symbol":"RNAZ"},"owners":[{"id":109315,"kind":"person","name":"Dudley Robert Michael","position":1,"cik":"0001854161","reported_name":"Dudley Robert Michael","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-06-22T18:23:24.000Z","date":"2023-06-20","kind":"purchase","planned":false,"acquired":true,"shares":6607,"price":2.5498,"value":16846.5286,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects the weighted average purchase price for shares of common stock purchased. Actual purchase prices for the shares purchased ranged from $2.54 to $2.55. The Reporting Person undertakes to provide TransCode Therapeutics, Inc. (the \"Company\"), any security holder of the Company or the staff of the Securities and Exchange Commission full information regarding the number of shares purchased at each separate price."}],"balance_after":70262,"source":{"system":"sec-edgar","filing":"0001104659-23-073872","document":"tm2319496-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1854161/000110465923073872/tm2319496-1_4seq1.xml","form_type":"4"}},{"id":1856062,"issuer":{"id":8499,"kind":"organization","name":"Transcode Therapeutics, Inc.","symbol":"RNAZ"},"owners":[{"id":109315,"kind":"person","name":"Dudley Robert Michael","position":1,"cik":"0001854161","reported_name":"Dudley Robert Michael","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-06-14T16:16:17.000Z","date":"2023-06-09","kind":"purchase","planned":false,"acquired":true,"shares":19000,"price":2.76,"value":52440.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects the weighted average purchase price for shares of common stock purchased. Actual purchase prices for the shares purchased ranged from $2.675 to $2.85. The Reporting Person undertakes to provide TransCode Therapeutics, Inc. (the \"Company\"), any security holder of the Company or the staff of the Securities and Exchange Commission full information regarding the number of shares purchased at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"This Form 4/A amends the Form 4 originally filed on June 13, 2023 solely to correct the amount reported in Table I, Column 5. Due to an administrative error, the amount reported on the original Form 4 was not adjusted to reflect a 1-for-20 reverse stock split of the Company's common stock, which became effective as of May 22, 2023."}],"balance_after":61155,"source":{"system":"sec-edgar","filing":"0001104659-23-071204","document":"tm2318742-1_4aseq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1854161/000110465923071204/tm2318742-1_4aseq1.xml","form_type":"4/A","original_submission_date":"2023-06-13"}},{"id":1857396,"issuer":{"id":8499,"kind":"organization","name":"Transcode Therapeutics, Inc.","symbol":"RNAZ"},"owners":[{"id":109315,"kind":"person","name":"Dudley Robert Michael","position":1,"cik":"0001854161","reported_name":"Dudley Robert Michael","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-06-13T16:16:17.000Z","date":"2023-06-09","kind":"purchase","planned":false,"acquired":true,"shares":19000,"price":2.76,"value":52440.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects the weighted average purchase price for shares of common stock purchased. Actual purchase prices for the shares purchased ranged from $2.675 to $2.85. The Reporting Person undertakes to provide TransCode Therapeutics, Inc. (the \"Company\"), any security holder of the Company or the staff of the Securities and Exchange Commission full information regarding the number of shares purchased at each separate price."}],"balance_after":912114,"source":{"system":"sec-edgar","filing":"0001104659-23-070804","document":"tm2318573-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1854161/000110465923070804/tm2318573-1_4seq1.xml","form_type":"4"}},{"id":1884850,"issuer":{"id":8499,"kind":"organization","name":"Transcode Therapeutics, Inc.","symbol":"RNAZ"},"owners":[{"id":109315,"kind":"person","name":"Dudley Robert Michael","position":1,"cik":"0001854161","reported_name":"Dudley Robert Michael","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-05-19T20:06:54.000Z","date":"2023-05-19","kind":"grant","planned":false,"acquired":true,"shares":735000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable in full on December 31, 2023, subject to the Reporting Person's continued service at such time."}],"balance_after":735000,"derivative":{"exercise_price":0.2834,"expiration_date":"2033-05-18","underlying":"Common Stock","underlying_shares":735000},"source":{"system":"sec-edgar","filing":"0001104659-23-062813","document":"tm2316383-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1854161/000110465923062813/tm2316383-2_4seq1.xml","form_type":"4"}},{"id":2086632,"issuer":{"id":8499,"kind":"organization","name":"Transcode Therapeutics, Inc.","symbol":"RNAZ"},"owners":[{"id":109315,"kind":"person","name":"Dudley Robert Michael","position":1,"cik":"0001854161","reported_name":"Dudley Robert Michael","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-12-14T20:11:57.000Z","date":"2022-12-12","kind":"grant","acquired":true,"shares":135000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Thirty-three percent (33%) of the Stock Options shall vest and become exercisable on the one year anniversary of Vesting Commencement Date (December 1, 2022). Thereafter, the remaining sixty-seven percent (67%) of the Stock Options shall vest and become exercisable in 24 equal monthly installments on the last day of each such month following the first anniversary of the Vesting Commencement Date, provided the Reporting Person continues to have a Service Relationship with the Company on each vesting date."}],"balance_after":135000,"derivative":{"exercise_price":0.51,"expiration_date":"2032-12-11","underlying":"Common Stock","underlying_shares":135000},"source":{"system":"sec-edgar","filing":"0001104659-22-127084","document":"tm2232745-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1854161/000110465922127084/tm2232745-2_4seq1.xml","form_type":"4"}},{"id":2157504,"issuer":{"id":8499,"kind":"organization","name":"Transcode Therapeutics, Inc.","symbol":"RNAZ"},"owners":[{"id":109315,"kind":"person","name":"Dudley Robert Michael","position":1,"cik":"0001854161","reported_name":"Dudley Robert Michael","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-09-16T18:44:59.000Z","date":"2022-09-14","kind":"purchase","acquired":true,"shares":20000,"price":1.15,"value":23000.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.12 to $1.1761, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected."}],"balance_after":893114,"source":{"system":"sec-edgar","filing":"0001104659-22-100931","document":"tm2226100-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1854161/000110465922100931/tm2226100-1_4seq1.xml","form_type":"4"}},{"id":2249693,"issuer":{"id":8499,"kind":"organization","name":"Transcode Therapeutics, Inc.","symbol":"RNAZ"},"owners":[{"id":109315,"kind":"person","name":"Dudley Robert Michael","position":1,"cik":"0001854161","reported_name":"Dudley Robert Michael","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-06-01T16:01:27.000Z","date":"2022-05-31","kind":"purchase","acquired":true,"shares":2000,"price":1.8699,"value":3739.8,"ownership":{"direct":true},"balance_after":873114,"source":{"system":"sec-edgar","filing":"0001104659-22-067099","document":"tm2217388-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1854161/000110465922067099/tm2217388-1_4seq1.xml","form_type":"4"}},{"id":2249692,"issuer":{"id":8499,"kind":"organization","name":"Transcode Therapeutics, Inc.","symbol":"RNAZ"},"owners":[{"id":109315,"kind":"person","name":"Dudley Robert Michael","position":1,"cik":"0001854161","reported_name":"Dudley Robert Michael","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-06-01T16:01:27.000Z","date":"2022-05-27","kind":"purchase","acquired":true,"shares":28000,"price":1.8444,"value":51643.2,"ownership":{"direct":true},"balance_after":871114,"source":{"system":"sec-edgar","filing":"0001104659-22-067099","document":"tm2217388-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1854161/000110465922067099/tm2217388-1_4seq1.xml","form_type":"4"}},{"id":2414342,"issuer":{"id":8499,"kind":"organization","name":"Transcode Therapeutics, Inc.","symbol":"RNAZ"},"owners":[{"id":109315,"kind":"person","name":"Dudley Robert Michael","position":1,"cik":"0001854161","reported_name":"Dudley Robert Michael","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-02-03T06:03:35.000Z","date":"2022-02-01","kind":"grant","acquired":true,"shares":135000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Thirty-three percent (33%) of the Stock Options shall vest and become exercisable on the one year anniversary of Vesting Commencement Date (February 1, 2022). Thereafter, the remaining sixty-six percent (66%) of the Stock Options shall vest and become exercisable in 24 equal monthly installments on the last day of each such month following the first anniversary of the Vesting Commencement Date, provided the Reporting Person continues to have a Service Relationship with the Company on each vesting date."}],"balance_after":135000,"derivative":{"exercise_price":2.45,"expiration_date":"2031-01-31","underlying":"Common Stock","underlying_shares":135000},"source":{"system":"sec-edgar","filing":"0001104659-22-011081","document":"tm225233-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1854161/000110465922011081/tm225233-1_4seq1.xml","form_type":"4"}}]}